# Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection

> **NCT02738333** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 239 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** LDV/SOF
- **DRUG:** SOF
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT02738333
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-12
- **Primary completion:** 2017-02-14
- **Final completion:** 2017-05-11
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02738333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02738333, "Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02738333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*